Which has stronger valuation and earnings, IMUX or SGP?

Immunic is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is IMUX or SGP more profitable?

Spyglass Pharma's return on equity of -62.40% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Spyglass Pharma N/A -62.40% -24.83%

Which has higher valuation and earnings, IMUX or HELP?

Cybin is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Cybin N/A N/A -$148M -$3.02 N/A

Is IMUX or HELP more profitable?

Cybin's return on equity of -71.78% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Cybin N/A -71.78% -64.81%

Does the media favor IMUX or HELP?

In the previous week, Cybin had 22 more articles in the media than Immunic. MarketBeat recorded 24 mentions for Cybin and 2 mentions for Immunic. Immunic's average media sentiment score of 0.79 beat Cybin's score of 0.56 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, IMUX or ACHV?

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A

Is IMUX or ACHV more profitable?

Immunic's return on equity of -157.89% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Achieve Life Sciences N/A -511.12% -82.35%

Does the media favor IMUX or ACHV?

In the previous week, Achieve Life Sciences had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Achieve Life Sciences and 2 mentions for Immunic. Immunic's average media sentiment score of 0.79 beat Achieve Life Sciences' score of 0.32 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMUX or PHAT?

In the previous week, Immunic and Immunic both had 2 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 1.19 beat Immunic's score of 0.79 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunic (IMUX) Competitors

$16.46 -0.04 (-0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$16.62 +0.16 (+0.97%)

As of 06:34 PM Eastern

Compare

IMUX vs. SGP, HELP, ESPR, ACHV, and PHAT

Should you buy Immunic stock or one of its competitors? Immunic's main competitors and comparable companies include Spyglass Pharma (SGP), Cybin (HELP), Esperion Therapeutics (ESPR), Achieve Life Sciences (ACHV), and Phathom Pharmaceuticals (PHAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Immunic compare to Spyglass Pharma?

Immunic (NASDAQ:IMUX) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Spyglass Pharma's return on equity of -62.40% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Spyglass Pharma	N/A	-62.40%	-24.83%

Immunic is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Immunic had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 2 mentions for Immunic and 0 mentions for Spyglass Pharma. Immunic's average media sentiment score of 0.79 beat Spyglass Pharma's score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Positive
Spyglass Pharma	Neutral

Immunic currently has a consensus price target of $47.25, indicating a potential upside of 187.06%. Spyglass Pharma has a consensus price target of $44.00, indicating a potential upside of 67.56%. Given Immunic's stronger consensus rating and higher possible upside, research analysts clearly believe Immunic is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Immunic beats Spyglass Pharma on 9 of the 13 factors compared between the two stocks.

How does Immunic compare to Cybin?

Immunic (NASDAQ:IMUX) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Cybin is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Cybin's return on equity of -71.78% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Cybin	N/A	-71.78%	-64.81%

In the previous week, Cybin had 22 more articles in the media than Immunic. MarketBeat recorded 24 mentions for Cybin and 2 mentions for Immunic. Immunic's average media sentiment score of 0.79 beat Cybin's score of 0.56 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Immunic presently has a consensus price target of $47.25, indicating a potential upside of 187.06%. Cybin has a consensus price target of $48.60, indicating a potential upside of 273.27%. Given Cybin's higher possible upside, analysts clearly believe Cybin is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

51.8% of Immunic shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Immunic beats Cybin on 7 of the 13 factors compared between the two stocks.

How does Immunic compare to Esperion Therapeutics?

Immunic (NASDAQ:IMUX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Immunic had 2 more articles in the media than Esperion Therapeutics. MarketBeat recorded 2 mentions for Immunic and 0 mentions for Esperion Therapeutics. Immunic's average media sentiment score of 0.79 beat Esperion Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Positive
Esperion Therapeutics	Neutral

51.8% of Immunic shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Esperion Therapeutics has a net margin of 0.12% compared to Immunic's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Immunic presently has a consensus price target of $47.25, suggesting a potential upside of 187.06%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Immunic's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunic is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Esperion Therapeutics has higher revenue and earnings than Immunic. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Immunic has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Summary

Immunic beats Esperion Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Immunic compare to Achieve Life Sciences?

Immunic (NASDAQ:IMUX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Immunic has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market.

Immunic presently has a consensus target price of $47.25, suggesting a potential upside of 187.06%. Achieve Life Sciences has a consensus target price of $15.00, suggesting a potential upside of 88.92%. Given Immunic's higher probable upside, analysts plainly believe Immunic is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immunic's return on equity of -157.89% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

51.8% of Immunic shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Achieve Life Sciences had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Achieve Life Sciences and 2 mentions for Immunic. Immunic's average media sentiment score of 0.79 beat Achieve Life Sciences' score of 0.32 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immunic beats Achieve Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Immunic compare to Phathom Pharmaceuticals?

Immunic (NASDAQ:IMUX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunic has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Immunic has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Phathom Pharmaceuticals	$239.66M	2.92	-$221.25M	-$1.28	N/A

Immunic has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

In the previous week, Immunic and Immunic both had 2 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 1.19 beat Immunic's score of 0.79 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic currently has a consensus target price of $47.25, indicating a potential upside of 187.06%. Phathom Pharmaceuticals has a consensus target price of $22.86, indicating a potential upside of 163.94%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Immunic beats Phathom Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$224.58M	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-3.76	780.42	271.38	24.10
Price / Sales	N/A	785.30	638.95	90.12
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	-29.93	10.42	11.18	6.40
Net Income	-$97.17M	$2.79B	$3.46B	$348.28M
7 Day Performance	2.68%	2.25%	1.98%	0.91%
1 Month Performance	22.93%	4.72%	7.32%	5.10%
1 Year Performance	73.26%	7.07%	24.76%	16.16%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	2.5488 of 5 stars	$16.46 -0.2%	$47.25 +187.1%	+73.7%	$224.58M	N/A	N/A	70
SGP Spyglass Pharma	1.5918 of 5 stars	$25.78 -1.6%	$44.00 +70.7%	N/A	$875.95M	N/A	N/A	65
HELP Cybin	3.0382 of 5 stars	$11.57 -3.5%	$45.25 +291.1%	N/A	$840.05M	N/A	N/A	50	Analyst Revision
ESPR Esperion Therapeutics	N/A	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200
ACHV Achieve Life Sciences	2.9461 of 5 stars	$7.50 -1.2%	$15.00 +100.0%	+173.6%	$781.03M	N/A	N/A	20	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. SGP, HELP, ESPR, ACHV, and PHAT

How does Immunic compare to Spyglass Pharma?

Summary

How does Immunic compare to Cybin?

Summary

How does Immunic compare to Esperion Therapeutics?

Summary

How does Immunic compare to Achieve Life Sciences?

Summary

How does Immunic compare to Phathom Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. SGP, HELP, ESPR, ACHV, and PHAT

How does Immunic compare to Spyglass Pharma?

Is IMUX or SGP more profitable?

Which has stronger valuation and earnings, IMUX or SGP?

Do institutionals & insiders believe in IMUX or SGP?

Does the media prefer IMUX or SGP?

Do analysts rate IMUX or SGP?

Summary

How does Immunic compare to Cybin?

Which has higher valuation and earnings, IMUX or HELP?

Is IMUX or HELP more profitable?

Does the media favor IMUX or HELP?

Which has more risk and volatility, IMUX or HELP?

Do analysts recommend IMUX or HELP?

Do institutionals and insiders hold more shares of IMUX or HELP?

Summary

How does Immunic compare to Esperion Therapeutics?

Does the media prefer IMUX or ESPR?

Do insiders & institutionals hold more shares of IMUX or ESPR?

Is IMUX or ESPR more profitable?

Do analysts prefer IMUX or ESPR?

Which has preferable valuation & earnings, IMUX or ESPR?

Which has more risk & volatility, IMUX or ESPR?

Summary

How does Immunic compare to Achieve Life Sciences?

Which has more risk & volatility, IMUX or ACHV?

Do analysts rate IMUX or ACHV?

Is IMUX or ACHV more profitable?

Which has better earnings & valuation, IMUX or ACHV?

Do institutionals and insiders believe in IMUX or ACHV?

Does the media favor IMUX or ACHV?

Summary

How does Immunic compare to Phathom Pharmaceuticals?

Do insiders & institutionals believe in IMUX or PHAT?

Is IMUX or PHAT more profitable?

Which has better valuation and earnings, IMUX or PHAT?

Which has more risk and volatility, IMUX or PHAT?

Does the media prefer IMUX or PHAT?

Do analysts rate IMUX or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools